RAPT Therapeutics, Inc. (RAPT)

20.74 -0.31 (-1.47%) At close: 4:00PM EST

RAPT Therapeutics, Inc.

561 Eccles Avenue
South San Francisco, CA 94080
United States
650 489 9000
http://www.rapt.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 71

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Brian Russell Wong	CEO, Pres & Director	912.2k	N/A	1972
Mr. Rodney K. B. Young	CFO & Sec.	132.08k	N/A	1963
Dr. Dirk G. Brockstedt Ph.D.	Chief Scientific Officer	427.77k	N/A	1969
Steve Young Ph.D.	VP of Technology	N/A	N/A	N/A
Ms. Phyllis Loud Gray	VP of HR	N/A	N/A	N/A
Dr. Paul Kassner	Sr. VP of Quantitative & Computational Biology	N/A	N/A	1967
Dr. David Wustrow	Sr. VP of Drug Discovery & Preclinical Devel.	N/A	N/A	1959
Dr. William Ho	Chief Medical Officer	N/A	N/A	1965
Ms. Karen C. Lam	VP of Fin. & Corp. Controller	N/A	N/A	1974

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Corporate Governance

RAPT Therapeutics, Inc.’s ISS Governance QualityScore as of December 1, 2020 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.